Drug Profile


Alternative Names: CaCP 29; IFX-1

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Beijing Mabworks Biotech; InflaRx
  • Developer InflaRx
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5a inhibitors; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hidradenitis suppurativa; Sepsis; Systemic inflammatory response syndrome
  • Phase I Inflammation

Most Recent Events

  • 01 Jan 2017 InflaRx completes a phase II trial in Systemic inflammatory response syndrome in Germany (NCT02866825)
  • 04 Nov 2016 Phase-II clinical trials in Hidradenitis suppurativa in Greece (IV) (EudraCT2016-002988-33)
  • 03 Mar 2016 Phase-I clinical trials in Inflammation in Germany (IV) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top